NEUROTERA: For the placing on the market of new therapeutic agents against ocular and cerebral comorbidities associated with paramyloidosis (Q2907213): Difference between revisions
Jump to navigation
Jump to search
(Changed label, description and/or aliases in en: translated_label) |
(Removed claim: co-financing rate (P837): 66.0 percent, Removing co-finance rate from projects in portugal) |
||||||
| Property / co-financing rate | |||||||
| |||||||
| Property / co-financing rate: 66.0 percent / rank | |||||||
Revision as of 11:56, 14 September 2021
Project Q2907213 in Portugal
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | NEUROTERA: For the placing on the market of new therapeutic agents against ocular and cerebral comorbidities associated with paramyloidosis |
Project Q2907213 in Portugal |
Statements
891,220.51 Euro
0 references
16 August 2016
0 references
15 February 2020
0 references
BSIM THERAPEUTICS, S.A.
0 references
Q2988326 (Deleted Item)
0 references
Identifiers
POCI-01-0247-FEDER-003431
0 references